Predicting post-surgery treatment for liver cancer using AI and whole-slide images

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study tests a deep learning model that integrates whole-slide pathology images and radiologic data to predict response to adjuvant therapies after liver cancer resection. It focuses on hepatocellular carcinoma patients who have undergone curative resection and have complete tissue, imaging, and clinical data. The goal is to identify which patients may benefit from adjuvant transarterial chemoembolization or tyrosine kinase inhibitor therapy. The approach leverages tumor immune microenvironment and multimodal imaging features to guide personalized post-surgical treatment decisions. The study is conducted at Zhejiang University's Second Affiliated Hospital in Hangzhou, with a lead sponsor coordinating the effort.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histopathologically confirmed hepatocellular carcinoma;
* Aged more than 18 years;
* Underwent radical resection of primary liver cancer (R0 resection);
* Availability of postoperative H\&E-stained paraffin embedded tissue sections suitable for digital whole-slide imaging;
* Had complete and accessible clinicopathological data and follow-up data;
* Has complete and evaluable preoperative and postoperative contrast-enhanced CT or MRI imaging with standardized scanning parameters and no severe artifacts, meeting the quality requirements for radiomic and artificial intelligence analysis.

Exclusion Criteria:

* Significant missing clinical or follow-up data;
* Concurrent primary malignancy in other organs;
* Positive surgical margin (R1 or R2 resection);
* Tissue sections of poor quality (e.g., severe fading, folding, damage) unsuitable for digital scanning or analysis;

Where it's running

• the Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: ding yuan, doctor
• Email: dingyuan@zju.edu.cn
• Phone: +86 18858101960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing DEB-TACE and cTACE for liver cancer after TIPS

  This trial will test whether DEB-TACE or conventional TACE works better and is safer for people with hepatocellular carcinoma beyond Milan criteria who previously had a TIPS.

  Recruiting Phase 3 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07322848

• Post-surgery radiotherapy plus sintilimab versus TACE for liver cancer with narrow surgical margins

  This trial will try to see if adding radiotherapy and the immunotherapy drug sintilimab after curative liver cancer surgery prevents recurrence better than TACE in patients with narrow surgical margins and other high-risk features.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07186621

• Combining Lenvatinib, Tislelizumab, and TACE for Liver Cancer Treatment

  This study is testing a new combination treatment for liver cancer to see if it can help patients at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05920863

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.